Intellicell Biosciences Inc (fka SVFC)

[Nadendla]

SVFC DUE DILIGENCE!!



The transfer agent for the company is Continental and the float is approximately 27M. There are 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants.

CONTACT:

[e-mail]
[e-mail]
[e-mail]
T: 646.576.8710
C: 917.209.6636
F: 212.249.1482


INTELLICELL BIOSCIENCES Management has identified a number of acquisitions which could be negotiated that might be helpful to IntelliCell BioSciences in moving forward rapidly and solidifying its position as the technology leader in the Regenerative Medicine field in the United States and abroad

..In addition to Millipore Corporation, which now has an agreement with IntelliCell BioSciences, management and its representatives have been in discussion with other major pharmas and generic pharmaceutical companies about various partnerships and licensing arrangements for many of IntelliCell’s key products, both in the United States and overseas.

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/

On October 13,2011..This stock is to trade @$4.80 at its peak on NASDAQ....On March 15 2012...this traded @ $2.20 ...At that time the company never had the latest patents that they have now...

New Approved Powerful Patent..Which can be a Game Changer..

http://ih.advfn.com/p.php?pid=nmona&article=57985645

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,440,440.PN.&OS=PN/8,440,440&RS=PN/8,440,440

United States Patent 8,440,440
Victor May 14, 2013
Ultrasonic cavitation derived stromal or mesenchymal vascular extracts and cells derived therefrom obtained from adipose tissue and use thereof

Abstract
Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells.

Inventors: Victor; Steven (New York, NY)
Applicant:
Name City State Country Type

Victor; Steven
New York
NY
US
Assignee: Intellicell Biosciences Inc. (New York, NY)
Family ID: 46317059
Appl. No.: 13/323,030
Filed: December 12, 2011

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent, our technology is now protected and we expect our international patent publication in a short time."


..So..The International patent will be approved in a short time..



...and the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013 ..which is now..the FDA approval news will hit anytime...

http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert

The company also intends to explore combination therapies with patent pending bio-engineered products under development....he Company believes that the IntelliCell product is an efficient cellular delivery platform for a variety of therapeutic applications and will look to partner with technology developers...

...clearly means that there are more patents applied for and which are pending...

http://www.stemcellcafe.com/regenerative-medicine/intellicell-biosciences-announces-collaborative-agreement-with-the-university-of-florida-on-stem-cell-and-tissue.php

After a recent capital raising, the company has projected to have $1.5 million of cash and no debt.


http://www.proactiveinvestors.com/companies/news/26420/cpreportscom-says-intellicells-therapy-a-game-changer-26420.html

Revenues are already flowing through licensing..@ a million Dollars per licensing ..amazing revenue stream..their patents/technology can be licensed to other parties for a fee..each licensing earns them about a million dollars..the 2 licensing deals as under..

www.sec.gov/Archives/edgar/data/1125280/000101376212000880/form10k.htm

In consideration for the grant of the exclusive license, the licensee agreed to pay us an up-front license fee of $1,000,000 payable as follows: (i) an initial installment of One Hundred Fifty Thousand Dollars ($150,000) upon execution of the agreement; (ii) One Hundred Thousand Dollars ($100,000) within three (3) days of the completion of the Lab Equipment (as defined in the agreement) having been delivered and installed (in accordance with applicable cGMP’s and cGTP’s of the US FDA) and the Lab Technician (as defined in the agreement) for the initial Laboratory Facility (as defined in the Thailand Agreement) having completed training; and (iii) the balance of Seven Hundred Fifty Thousand Dollars ($750,000) to be placed in escrow with counsel for the Company upon the payment of the second installment, with such funds to be held in escrow for a period of ninety (90) days, with such funds to be released upon satisfaction by the parties that the Lab Equipment is in working order and the Lab Technician has been adequately trained.

The other recently concluded licensing agreement in Australia..

Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology!!..Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales!!..and this is just one of many ..Just the beginning..

Thursday, June 20, 2013

www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent


Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales.

Intellicell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue. This process dramatically increases the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods in use today. Intellicell’s process generates between half billion - 1.4 billion SVFC cells from 60 ccs from a patient’s own adipose tissue. This is approximately 10-20 times greater than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely excited about our licensing partnership with Cell-Innovations, Inc. We believe they are one of the best positioned companies to market the Intellicell technology in Australia & New Zealand.


Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine market by providing innovative IntelliCell technology to the Australian and New Zealand marketplace. We believe that IntelliCell technology will be a “game-changer” in the regenerative medicine field making available stromal vascular fraction (SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD a founder of Australian Cell Technologies, a company introducing regenerative cellular products to the veterinary market. Dr. Thomas has 25 years experience in cell biology and developed kits for adipose SVF for the veterinary market. Dr. Thomas’ research contributions has been recognized by many publications and book chapters, and is a reviewer for both national and international granting bodies and journals; and, will be a scientific advisor for IntelliCell. Dr Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer in stromal vascular fraction treatments in Australia, a Fellow and Member of many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been treating patients with adipose SVF since 2009 for osteoarthritis and degenerative neurological disease and is one of the most experienced physicians in Australia in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence’ where doctors can treat their patient”

...with Revenues of 2 million dollars out of just 2 Licensing deals..the company makes close to 2 million dollars..imagine 50 deals ..world wide..or a hundred..it would be insane Revenue Generation..and the PPS will reflect the same ....


MERCK subsidiary Millipore collaborating with Intellicell Biosciences..Millipore(American Subsidiary of MERCK)has executed an exclusive supply and sale agreement with IntelliCell BioSciences to sell and distribute the guava flow cytometry platform into the area of SVF..

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/


Here is Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore(American Subsidiary of MERCK) sitting on the Board of Advisors..

http://www.intellicellbiosciences.com/corporate-profile.html

Medical Board of Advisors


Dr. James Andrews, The Andrews Institute
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

http://www.millipore.com/company/flx4/about

https://lists.purdue.edu/pipermail/cytometry/2012-February/042840.html

Headquartered in Billerica, Massachusetts, EMD Millipore has some 10,000 employees in 67 countries motivated by the potential of science for life through a portfolio of more than 40,000 products. Comprised of three business units—Bioscience, Lab Solutions, and Process Solutions— EMD Millipore is a top tier supplier to the life science industry, and serves as a strategic partner for scientists, engineers, and researchers. For more information on the EMD Millipore portfolio, vision and mission, as well as careers, events and current news, refer to our divisional section.


EMD Millipore Headquarters
290 Concord Road
Billerica, MA 01821
978.715.4321
The EMD Group

EMD Millipore is part of the The EMD Group, a global pharmaceutical and chemical company which generated total revenues of EUR 9.3 billion in 2010 and has 40,000 dedicated employees worldwide. In North America, Merck, Darmstadt, Germany operates under the umbrella brand EMD (EMD Millipore), formed from the initials of Emanuel Merck, Darmstadt.


Intellicell Biosciences are the only public commercial stem cell company in the United States. IntellicellTM is the only company in the U.S. to meet FDA (Law 361) guidelines for this procedure!!.



http://www.princetonresearch.com/biosciences-news-intellicell-biosciences-inc-symbol-svfc-investment-research-report-issued/

Veteran Wall Street analyst Ray Dirks said Intellicell's SVF cell therapy was a thousand times more potent than the current therapy of cortisone for treating inflammation, but it also re-grows tissue, cartilage, and blood vessels...

A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Sommerfeldt’s basketball career was saved through IntelliCell's proprietary SVF cell therapy

http://www.proactiveinvestors.com/companies/news/26420/cpreportscom-says-intellicells-therapy-a-game-changer-26420.html

Intellicells technology produces 10 times more number of SVF cells containing adult adipose stem cells from less than any of its present competition ..including CYTORI(CY*X)...

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.

Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology!!..Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales!!..and this is just one of many ..Just the beginning..

Thursday, June 20, 2013

http://www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent


IntelliCell plans to collaborate with International Partners to achieve optimal market entry opportunities and revenues.

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/

..Millipore(MERCK) is already in...whose next...




Intellicell Biosciences is compared to CYTORI on seekingalpha.com..Only Intellicell biosciences seems to have a far better tech as below..

http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert

The IntelliCell process, branded IntelliSonics, is similar to the Cytori process in that they both use lipoaspirate. But the IntelliCell process produces a different cellular population because, with its sonification [ultrasound] process, the blood components are not washed out[/color]. The stromal vascular fraction of IntelliCell contains the hematopoietic cells. The final product is quality-controlled, checked for any contamination and cell viability is measured.

IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.

Dr. Steven Victor, is also the founder of ReGen Medical. ReGen Medical is a state-of-the-art hospital in midtown Manhattan that provides stromal vascular fraction cellular therapy, which contains stem cells, to patients today. The hospital is a beautiful, brand-new facility that treats high-end patients.

The next move would be applying that new patent to the following..

IntelliCell also plans to partner with other technology developers in the industry to examine the use of Vascular Fraction Cells in a number of clinically relevant areas such as:

Hair Loss in Men and Women

Rheumatoid Arthritis

Multiple Sclerosis

ALS Disease

Autism

Tinnitus

Bone fractures

Osteoarthritis

Sports Medicine Injuries

Gingival Gum Regeneration

Dermal treatment for burns and non-healing wounds



Intellicell Bioscience's Stromal Vascular Fraction Stem Cell Therapy to treat non-healing diabetic foot ulcers...

http://www.complexwoundhealing.org/research/stromal-vascular-fraction-stem-cell-therapy-for-diabetic-foot-ulcers.html

The Winthrop Wound Healing Center is currently investigating a promising new regenerative medicine approach that uses the patient’s own stromal vascular fraction (SVF) cells—a blood component rich in adult stem cells, which can help stimulate the regeneration of healthy tissue. The SVF cells we will be using are obtained from blood vessels in the patient’s adipose (fat) tissue through a process that uses high-frequency ultrasound to break up the fat tissue, then separates out the SVF cells using a centrifuge.

Our wound center is currently working on plans to launch a clinical trial that will evaulate the benefits of using SVF cells to treat non-healing diabetic foot ulcers. In the trial, which will utilize SVF cells supplied by IntelliCell Biosciences, the stem-cell therapy will be administered to patients through a combination of intravenous infusion and topical injection into the wound site. The healing of DFUs and other chronic wounds is just one potential application for SVC-stem cell therapy: It is also being investigated as a possible treatment for osteoarthritis, gum cavity degeneration and multiple sclerosis.

SVFC

Revenues through licensing fees...



http://www.sec.gov/Archives/edgar/data/1125280/000101376212000880/form10k.htm

In consideration for the grant of the exclusive license, the licensee agreed to pay us an up-front license fee of $1,000,000 payable as follows: (i) an initial installment of One Hundred Fifty Thousand Dollars ($150,000) upon execution of the agreement; (ii) One Hundred Thousand Dollars ($100,000) within three (3) days of the completion of the Lab Equipment (as defined in the agreement) having been delivered and installed (in accordance with applicable cGMP’s and cGTP’s of the US FDA) and the Lab Technician (as defined in the agreement) for the initial Laboratory Facility (as defined in the Thailand Agreement) having completed training; and (iii) the balance of Seven Hundred Fifty Thousand Dollars ($750,000) to be placed in escrow with counsel for the Company upon the payment of the second installment, with such funds to be held in escrow for a period of ninety (90) days, with such funds to be released upon satisfaction by the parties that the Lab Equipment is in working order and the Lab Technician has been adequately trained.


LETS LOOK AT THE CHARTS...PEAK WAS $4.40...AND ON MARCH ,2012..SVFC WAS @$2.25...NOW 0.02 AND REVERSING...




https://www.google.com/finance?chdnp=1&chdd=1&chds=1&chdv=1&chvs=maximized&chdeh=0&chfdeh=0&chdet=1371347018608&chddm=448477&chls=IntervalBasedLine&q=OTCMKTS:SVFC&ntsp=0&ei=Pxi9UeDIB-mp0AHYvAE


TRANSFER AGENT: CONTINENTAL

FLOAT: 27 MILLION

AUTHORIZED SHARES: 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants.

Anna Rhodes <[e-mail]>
3:49 PM (4 minutes ago)

to me
Hi xxxx,

Thank you for your interest in IntelliCell BioSciences. The transfer agent for the company is Continental and the float is approximately 27M. There are 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants.

I hope this information is helpful to you.

Best regards,
Anna

Anna Rhodes
Executive Vice President of Operations
IntelliCell BioSciences, Inc.
460 Park Ave., 17th Floor
New York, NY 10022
T: 646.576.8710
C: 917.209.6636
F: 212.249.1482
E: [e-mail]
www.intellicellbiosciences.com

LETS LOOK AT THE MANAGEMENT...

INTELLICELL BIOSCIENCES CEO STEVEN VICTOR..

Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. Dr. Victor's interest in regenerative medicine began well over a decade ago with the clinical use of autologous fibroblast cells for the purpose of dermal regeneration. Dr. Victor received his medical degree from New York college and a Bachelor of Arts degree from New York University and has held hospital based teaching positions. He has been a sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology

Robert J. Sexauer, Executive Vice President Clinical Development

Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.

Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.

Anna Rhodes, Executive VP Operations

Anna Rhodes, our Executive Vice President of Operations, has been actively involved in the cosmetic and cosmeceuticals industries for over 9 years. From 2001 through 2009, Ms. Rhodes held various executive sales positions with Victor Cosmeceuticals, Inc. and Victor Products Inc., with primary responsibility for the development of many of the marketing and collateral materials, formulations and training materials for new product launches as well as managing international distribution. Prior to 2001, Ms. Rhodes held various sales positions in the high fashion industry with companies including Calvin Klein, Agnona and Michael Kors. She was a Magnum Cum Laude graduate of the University of Texas with a Bachelor of Science degree in Business Administration.

Sarah R. Young, Quality Assurance Manager

Prior to joing IntelliCell Ms. Young managed the QA departments for RTI Biologics, Inc. and Southeast Tissue Alliance, Inc. She is an experienced QA Director with nine years of experience working in high-volume manufacturing settings of human cellular and tissue-based products (HCT/Ps) and medical device products regulated under stringent good manufacturing practices (cGTPs/cGMPs) by the US Food and Drug Administration (FDA) as well as state specific statutes/regulations. She has held a Certified Tissue Bank Specialist certification from the tissue banking industry's quality standards setting organization, the American Association of Tissue Banks (AATB), since 2001, where she has also been a member of AATB's Quality Assurance Committee helping establish quality standards, guidances and providing training to the industry since 2005. She has experience with building new quality programs for partner agencies/satellite offices and training staff, writing standard operating procedures, engineering/designing validation protocols (R&D product development, processing, sterilization/decontamination, labeling, implementing effective corrective and preventive action systems, managing complaints and recalls, auditing and site inspections/qualifications, medical records management and healthcare experience, as well as prior experience with FDA.



LETS TAKE A LOOK AT THE HOT BLUE CHIP LUMINARIES OF THE BOARD OF DIRECTORS..

Leonard L. Mazur

COO Triax, Interim COO of IntelliCell BioSciences

Mr. Leonard L. Mazur Co-founded Triax Pharmaceuticals, LLC and serves as its Chief Operating Officer. Mr. Mazur also Co-Founded Akrimax Pharmaceuticals in 2007. Mr. Mazur began his pharmaceutical career with Cooper Laboratories in 1971, where he served as a Product Manager for ophthalmology, dermatology and other products. He was responsible for creating and growing the business that was sold to Pierre Fabre, a French dermatology company, in 2002. In 1995, he founded Genesis Pharmaceutical, Inc., and served as its Chairman, Chief Executive Officer from 1995 to 2005 and President. In 1989, he became one of the first employees of Medicis Pharmaceuticals, a start-up dermatology pharmaceuticals company. Mr. Mazur was responsible for acquiring brands, as well as sales and marketing. He was promoted to Marketing Manager with responsibility for the ethical OTC division where he managed sales and licensing. In 1984, he joined ICN Pharmaceuticals as Vice President of Marketing and Sales, and managed all aspects of the US pharmaceuticals group, including marketing, sales, licensing, and acquisitions. In 1981, he joined Knoll Pharmaceuticals as Director of Product Management. After a 2-year transition period, Mr. Mazur joined Krivulka in founding Triax. He serves as a Vice Chairman of Akrimax Pharmaceuticals. Llc. He has been a Director of PhotoMedex, Inc. since May, 2009.

Myron Z. Holubiak
President, 1-800-Doctors, Inc.

.....Recently joined Intellicell biosciences..Mr. Holubiak served as the President of Roche Laboratories, USA and was responsible for all U.S. operations including oversight of the development and launch of the obesity product Xenical

Mr. Myron Z. Holubiak serves as a Senior Partner of 1-800-Doctors.com Inc. and has been its President since May 2007. Mr. Holubiak serves as a Senior Executive with a broad background in the pharmaceutical industry and healthcare companies. He was a Partner of HealthSTAR Communications Inc., since 2002 and served as its Group President and Chief Operating Officer from November 2003 to April 2007 and also served as its Group President, Field Level Marketing Group from August 2002 to October 2003. Mr. Holubiak is an accomplished biotech and pharmaceutical senior executive with over 30 years of industry experience including directing Roche Laboratories. From August 2001 to June 2002, Mr. Holubiak served as the President and Chief Operating Officer of iPhysician Net Inc. From December 1998 to August 2001, Mr. Holubiak served as the President of Roche Laboratories, USA and was responsible for all U.S. operations including oversight of the development and launch of the obesity product Xenical (R). Previously, he spent 19 years in a variety of marketing, sales and executive positions with Roche Laboratories. Mr. Holubiak co-founded Emron Inc., and served as its Chief Executive Officer. He has been Chairman of the Board at BioScrip Inc. since April 18, 2012. He has been a Director of BioScrip Inc., since March 2005, and of Ventrus Biosciences Inc., since July 2010. He has been Director of IntelliCell BioSciences, Inc since October 2012. He serves as a Director of US Wellness Inc. and 1-800-Doctors.com. Mr. Holubiak served as a Director of Chronimed, LLC (also known as Chronimed Inc.), since October 28, 2002. He served as a Director of iPhysician Net Inc., from August 2001 to June 2002. He served as a Director of MDRNA Inc. (now, Marina Biotech, Inc.) since June 2004. He serves as a Director of the Children of Chernobyl Relief Foundation. Mr. Holubiak was a Trustee of the Robert Wood Johnson Hospital Foundation from 2000 to 2001. He was a Founding Member of the Academy of Managed Care Pharmacy, the professional society of managed care pharmacists. Mr. Holubiak holds a BS in Molecular Biology and Biophysics from the University of Pittsburgh in 1969 and a graduation in Biophysics from the University of Pittsburgh in 1970 and has completed medical training.

Micheal Hershman ..who recently joined the Board of Directors of Intellicell biosciences..For the past 12 years he has been a member of Interpol’s International Group of Experts on Corruption and NOW SERVES AS THE CHAIRMAN and also the FOUNDER of the FAIRFAX GROUP!!...



http://www.fairfaxco.us/bio_hershman.php

Michael Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. The Fairfax Group, founded in 1983, has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the conduct of senior-level officials and/or the entities with which they do business.

Mr. Hershman has been called upon repeatedly to respond in times of crisis by governments, public and private companies, law firms and individuals. In high profile controversies, criminal prosecutions and civil litigation, Fairfax has participated in some of the most prominent disputes around the world for the last twenty-eight years. From high profile events, like the Olympics and Super Bowls, to targeted terrorist attacks, Fairfax has responded to provide assistance to individuals and entities facing serious, wide-spread threats against their persons and property. Fairfax has provided litigation support, state-of-the-art digital forensics and security measures, crisis monitoring and response, and advice to corporate boards and executives and governments in the midst of some of the most contentious situations.

In December 2006, for example, Mr. Hershman was appointed as the independent compliance advisor to the board of directors of Siemens AG, a company with more than 400,000 employees. Similarly, The Fairfax Group has assisted governments from India to Chile on ethics matters, and has served as the appointed monitor of companies that have violated laws, rules or regulations.

Mr. Hershman began his career in intelligence and investigations in Europe during the late 1960s as a special agent with U.S. Military Intelligence, specializing in counter-terrorism. After leaving the military, he moved to investigations of government misconduct and financial fraud for the New York State Attorney General's Office and the Office of the Mayor of New York City.

Later, Mr. Hershman served as a senior staff investigator for the Senate Watergate Committee, and as chief investigator for a joint Presidential and Congressional commission, reviewing state and federal laws on wiretapping and electronic surveillance. After the wiretap commission hearings, Mr. Hershman joined the Federal Election Commission as chief investigator, where he was responsible for audits and investigations of candidates and their campaign committees.

Mr. Hershman then served as deputy staff director for the Subcommittee on International Organizations of the U.S. House of Representatives, which was responsible for legislation and oversight relating to international banks and other U.S. supported international organizations, such as the United Nations.

Immediately prior to founding the Fairfax Group, Mr. Hershman served as deputy auditor general for the Foreign Assistance Program of the U.S. Agency for International Development (AID), where he led investigations and audits of major U.S. funded projects overseas, and was responsible for worldwide security at all foreign AID missions. Mr. Hershman was awarded the Superior Honor Medal for his service at AID.

In 1993, along with Peter Eigen, Mr. Hershman co-founded Transparency International, the largest independent, not-for-profit coalition promoting transparency and accountability in business and in government. For the past 6 years he has served Interpol as a member of the International Group of Experts on Corruption, and for the past 12 years, he has sat on the board of the International Anti-Corruption Conference Committee.

Mr. Hershman is a member of the board of directors of the U.S. Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues. Since 2007, Mr. Hershman has been a member of the board of directors and the executive committee of the Center for International Private Enterprise.

For the past 12 years he has been a member of Interpol’s International Group of Experts on Corruption and now serves as Vice Chairman. He is also on the board of the International Anti-Corruption Conference Committee. He also serves on the Financial Coalition against Child Pornography, a project of the National Center for Missing and Exploited Children. Additionally, he is a member of the Advisory Council of the George Mason University School of Information Technology and Engineering.

Since 2008, he has been named every consecutive year to the Ethisphere Institute’s list of the top 100 most influential people in business ethics worldwide.

Michael Hershman has given hundreds of speeches throughout the world on issues related to transparency and accountability and has provided commentary on ABC, CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as countless national radio shows. For five years he was the co-host of the Public Radio Law Show. He has been quoted and published in the Wall Street Journal, the New York Times, the New York Post, the Washington Post, USA Today, the Financial Times, the National Law Journal and other print media.

http://www.fairfaxco.us/images/bios/interpol_10_11.jpg

Harry Fisch,MD..who joined Intellicell Biosciences...Dr. Harry Fisch is a board certified urologist and is one of the nation's leaders in the diagnosis and treatment of Men's health issues. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and varicocele repair. He has been named to the “Best Doctors in America" and "New York Magazine Top Doctors" the past 9 years. He regularly appears on The Dr. Oz Show as a medical expert on Men's Health and hosts The Harry Fisch Show on Howard 101 which helps men with their most intimate problems and needs.

http://www.harryfisch.com/#sthash.pwfrJrb4.dpuf

http://www.harryfisch.com/

Dr. Arnold I. Caplan...father of the Mesenchymal stem cells..

..Joins Intellicell Biosciences ..Board of Directors..

http://www.biospace.com/News/intellicell-biosciences-announces-dr-arnold-i/263167

Dr. Caplan is a Professor of Biology & General Medical Sciences and Director of the Skeletal Research Center at Case Western Reserve University in Cleveland, Ohio. Professor Caplan has published over 300 manuscripts and articles in peer reviewed journals. Dr. Caplan has been Chief Scientific Officer at OrthoCyte Corporation since 2010. Dr. Caplan co-founded Cell Targeting Inc. and has served as President of Skeletech, Inc. as its founder. He served as Chief Scientific and founder of Osiris Therapeutics, Inc. He has served as Director of BioMetic Pharmaceuticals, Inc. and Carbylan Biosurgery. Also, he has been a Director of Biomimetics Pharmaceuticals, Inc. Dr. Caplan has served as a Member of the Scientific Advisory Board at IsoTis Orthobiologics. He is the recipient of several honors and awards from the orthopedic research community. Dr. Caplan holds a Ph. D. from John Hopkins University Medical School and a B.S. in chemistry from the Illinois Institute of Technology.[/quote]

Dr. Zain Khalpey ..joins Intellicell biosciences...

http://www.otcmarkets.com/stock/SVFC/news



http://uanews.org/story/ua-surgeon-works-to-revolutionize-organ-transplantation

http://ahsc.arizona.edu/vnr/dr-zain-khalpey-spotlight-video

Born in Africa, Dr Khalpey completed his medical education in the UK and studied and worked extensively throughout Europe and the United States before deciding to pursue his organ transplantation research at the University of Arizona, the birthplace of the Total Artificial Heart.

In addition to his clinical work at The University of Arizona Medical Center, where he recently was appointed director of the internationally renowned heart transplant program and mechanical circulatory support, Khalpey is involved in numerous research activities, focused mainly in three key areas: bridge to regeneration, organ reconditioning and organogenesis, or the creation of new organs.

The first area, bridge to regeneration, focuses on reducing the number of people who require heart transplants by improving stem cell treatments for failing hearts.

In patients requiring heart transplants, mechanical devices known as ventricular assist devices often are used to keep their failing hearts functioning while they wait for donor organs. The devices act as "a bridge to transplant." Khalpey would like to use those same devices instead as "a bridge to regeneration," as he aims to regenerate failing hearts with stem cell injections.

To date, clinical trials involving stem cell therapies for failing hearts have had limited success. Khalpey is involved in a series of clinical trials and studies exploring ways to improve the process. Among his efforts, he's working on transforming the cells from being pluripotent - able to differentiate into essentially any part of the body - to being multipotent - tailored to differentiate into only certain areas, such as the heart.

Khalpey's second research area, organ reconditioning, focuses on increasing the pool of donor lungs for patients requiring a lung transplant by taking donor lungs that would be thrown away and making them suitable for transplant.

He is currently developing the UA's Ex Vivo Lung Program, which will explore new ways to recondition lungs from DCD (donation after cardiac death) donors, using mechanical devices and designer drugs to manipulate the metabolism of the organs and optimize them for transplantation.

This summer, the UA will serve as a national trial site for the Expand trial, comparing the survival of DCD lungs resuscitated on a mobile ex vivo circuit versus normal lungs transplanted.

In the event that an organ can't be reconditioned, Khalpey hopes it can still be put to use in his third area of research - organogenesis, which aims to grow new organs by combining an otherwise unusable donor organ with a transplant patient's own stem cells.

The idea is that a donor heart or lung could be put into detergent and decellularized so that nothing but the organ's matrix - essentially its skeleton - remains. The organ would then be seeded with the stem cells of a patient awaiting transplant and left to grow inside a special bioreactor, developed by Khalpey and his former colleagues at Harvard and Harvard Bioscience in Boston.

Khalpey and his colleagues have already used the bioreactor to successfully grow a new pig heart and lungs and they now are experimenting with human organs. The Donor Network of Arizona has pledged all the hearts and lungs it would normally throw away to help with the research efforts. With the organs that can't be reconditioned, Khalpey plans to create a "biofarm" of frozen organ cytoskeletons for use in future organogenesis research.

Khalpley also serves as director of the department of surgery's CAPTURED Biobank. His goal is to create a bank of cardiac and thoracic tissue with a stem cell directory that could be used by medical researchers worldwide. Human stem cells would be harvested during operations, with patient consent, for future use in tissue engineered heart valves, lungs and other organs.

Finally, Khalpey also is looking at the long-range possibility of creating transplantable human hearts and lungs using a 3-D bioprinter.

Three-dimensional printing, which produces three-dimensional solid objects from digital models, has been used to create things such as architectural models, jewelry and dental crowns. Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, has used the technology to engineer a lab-grown human bladder that was successfully transplanted into a patient in 2007.

Khalpey envisions doing the same thing with hearts and lungs, seeding a printed collagen or elastic organ structure with human stem cells and putting it into the bioreactor to develop.

Heart Surgeon Zain Khalpey Appointed to Lead Heart Transplant Program &
Mechanical Circulatory Support Surgery Program at UAMC

http://diabeticfootonline.blogspot.com/2013/03/zain-khalpey-to-lead-uofa-heart.html

TUCSON, Ariz. – Zain Khalpey, MD, PhD, MRCS (Eng), has joined the University of Arizona Department of surgery as associate professor in the Division of Cardiothoracic Surgery. He has been appointed surgical director of the Heart Transplant and Mechanical Circulatory Support Program at The University of Arizona Medical Center – University Campus.

Specializing in heart surgery for adults and children, Dr. Khalpey comes to the UA from Columbia University in New York City, where he also has a tenure track appointment in cardiothoracic surgery. His surgical interests include adult and pediatric heart transplant, mechanical circulatory support (ventricular-assist devices and total artificial heart), ex vivo lung perfusion, minimally invasive treatments for valve disease, arrhythmia surgery and robotic mitral valve surgery.

In his research role at the UA, he is the director of the Ex Vivo Lung Program, clinical and translational research, and the Cardiopulmonary Stem Cell Bank. Dr. Khalpey also holds a position on the UA Institutional Review Board (IRB).

Dr. Khalpey’s research on translational tissue regeneration evolved from past basic science studies in metabolomics and cell survival. His laboratory at the UA focuses on basic and translational research on organogenesis (the formation and development of organs), organ preservation and tissue regeneration.

Dr. Khalpey is engaged in ex vivo reconditioning of marginal human hearts and lungs, which will generate functional lung and heart tissue that ultimately can be used for transplantation. This reconditioning process uses human cadaveric lungs that are decellularized (chemically stripped of its cells, leaving behind the extracellular tissue and lung scaffolds). That structure is “re-seeded” with autologous stem cells to rebuild the organ.

He also is involved in creating clinical “bridge-to-regeneration” trials, in which autologous stem cells will be injected into failing hearts with the hope of recovery in an era of limited hearts for transplantation.

Dr. Khalpey has published more than 100 manuscripts, abstracts and book chapters in heart and lung transplantation in basic science and clinical outcome studies. He is an American Heart Association reviewer and Early Career Reviewer for the National Institutes of Health (NIH). He has received numerous teaching and institutional awards, including the Hunterian Medal and Professorship of Surgery from Royal College of Surgeons, England; the Winston Churchill Medal, bestowed by HRH Queen Elizabeth II, Winston Churchill Memorial Trust, London, UK; Excellence in Teaching Award, Harvard University; United Nations Educational, Scientific and Cultural Organization (UNESCO) Fellowship from Switzerland and France; and the Solly Medal and Prize for Surgery from the University of London.

“The combined training, aptitude and skills of Dr. Khalpey represent the future of cardiac surgery,” said Robert Poston, MD, chief, Division of Cardiothoracic Surgery. “He has tremendous promise as a surgeon who successfully will bridge the gap between the theories of basic science research and practical innovation in clinical medicine and surgery. I am extremely excited to add him as a critical partner to our growing CT team.”

“We are very happy to have a surgeon and researcher of Dr. Khalpey’s caliber join the cardiothoracic team,” saidRainer W.G. Gruessner, MD, chairman, UA Department of Surgery. “The cardiac surgery program has a national reputation as a pioneer in heart transplantation, in developing new heart devices and for providing the highest levels of patient care for patients suffering from heart failure. The addition of Dr. Khalpey will serve to further strengthen this outstanding program for the residents of Tucson and beyond.”

DR.ANDREWS WHO JOINED INTELLICELL BIOSCIENCES…

http://www.intellicellbiosciences.com/corporate-profile.html

Doctor James Andrews is one of the founding members of Andrews Sports Medicine and Orthopaedic Center in Birmingham, Alabama. He is also a founder of the American Sports Medicine Institute (ASMI) a non-profit institute dedicated to injury prevention, education and research in orthopaedics and sports medicine. This foundation is recognized as one of the world’s leaders in this field. Doctor Andrews is internationally known and recognized for his skills as an orthopaedic surgeon as well as his scientific and clinic research contributions in knee, shoulder and elbow injury prevention and treatment. In addition, he has made major presentations on every continent, and has authored numerous scientific articles and books.

Doctor Andrews graduated from Louisiana State University (LSU) in 1963, He completed LSU School of Medicine in 1967 and completed his orthopaedic residency at Tulane Medical School in 1972. He had surgical fellowships in sports medicine at the University of Virginia School of Medicine in 1972 with Doctor Frank McCue, III and at the University of Lyon, Lyon, France in 1972 with the late professor Albert Trillat, M.D., who is known as the Father of European Knee Surgery.

Doctor Andrews is a member of the American Board of Orthopaedic Surgery and the American Academy of Orthopaedic Surgeons. He is President-Elect of the American Orthopaedic Society for Sports Medicine and was Secretary of that Board from May 2004 to May 2005.

At present, Doctor Andrews serves as Medical Director for Intercollegiate Sports at Auburn University; Senior Orthopaedic Consultant at the University of Alabama; and Orthopaedic Consultant for the athletic teams of Troy University, University of West Alabama, Tuskegee University and Grambling University. Doctor Andrews serves on the Medical and Safety Advisory Committee of USA Baseball and on the Board of Little League Baseball, Inc.

In the professional sports arena, Doctor Andrews is Senior Consultant for the Washington Redskins Professional Football team; Medical Director for the Tampa Bay Rays Professional Baseball Team; and team physician for the Birmingham Barons Double A Professional Baseball Team, an affiliate of the Chicago White Sox. Doctor Andrews is the Co-Medical Director of the Ladies Professional Golf Association.

Medical Board of Advisors


Dr. James Andrews, The Andrews Institute
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute

DR.ANDREWS IS A FAMOUS PHYSICIAN FOR SUPERSTARS…

TAKE A LOOK AT THE LIST OF STARS HE TREATED….

The list below is from 5years ago, not counting the new ones,

http://www.fastcompany.com/958565/star-power-dr-andrews-patient-list-veritable-whos-who-sports

1. John Smoltz, Tommy John surgery, shoulder surgery;
2. Michael Jordan, shoulder exam;
3. Pavel Bure, knee consultation;
4. Scottie Pippen, elbow surgery;
5. Barry Zito, biomechanics lab;
6. Kenny Rogers, Tommy John;
7. Paul Molitor, shoulder surgery;
8. DwyAne Wade, shoulder consultation;
9. Tiger Woods, knee consultation;
10. Derek Jeter, shoulder consultation;
11. Vince Carter, knee exam;
12. Donovan McNabb, knee surgery;
13. Shaquille O'Neal, shoulder consultation;
14. Emmitt Smith, shoulder surgery;
15. Jim Rice, elbow tendon surgery;
16. Jeremy Roenick, knee consultation;
17. Charles Barkley, shoulder surgery;
18. Roger Clemens, shoulder surgery;
19. Gary Sheffield, shoulder surgery;
20. David Wells, Tommy John;
21. Jorge Posada, shoulder surgery;
22. Mike Schmidt, shoulder surgery;
23. Alexandra Stevenson, shoulder surgery;
24. Jack Morris, shoulder consultation;
25. Reggie Bush, knee consultation;
26. Chris Carpenter, elbow surgery;
27. Kerry Wood, Tommy John;
28. Michael Irvin, shoulder surgery;
29. Matt Morris, Tommy John;
30. Andy Pettitte, elbow tendon surgery;
31. Alex Smith, shoulder consultation;
32. Steve Carlton, shoulder surgery;
33. Jonathan Papelbon, biomechanics program;
34. Jack Nicklaus, knee surgery;
35. Cecil Fielder, shoulder surgery;
36. Tim Raines, shoulder surgery;
37. Andre Dawson, knee surgery;
38. Chris Webber, knee surgery;
39. Bruce Smith, knee surgery;
40. Chad Pennington, shoulder surgery;
41. Matt Hasselbeck, shoulder surgery;
42. Allen Iverson, elbow surgery;
43. Joey Porter, knee surgery;
44. Tim Hudson, biomechanics lab;
45. Bo Jackson, shoulder surgery, hip replacement;
46. Mariano Rivera, consultation;
47. David Cone, shoulder surgery;
48. Matt Leinart, broken-collarbone consultation;
49. Albert Pujols, elbow consultation;
50. Drew Brees, shoulder surgery;
51. Daunte Culpepper, knee surgery;
52. Peyton Manning, knee surgery;
53. Eli Manning, shoulder consultation;
54. Brady Quinn, knee consultation;
55. George Brett, knee surgery;
56. Gary Carter, knee surgery;
57. Jim Thome, elbow tendon surgery;
58. Marvin Harrison, knee surgery;
59. Bill Elliott, leg surgery;
60. Hulk Hogan, knee surgery;
61. Troy Aikman, elbow and shoulder surgeries;
62. Josh Beckett, annual exam



Intellicell Biosciences at the Wallstreet Conference..

http://www.wallstconference.com/







GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO SVFC